Antimicrobial Resistance (AMR) is a huge economic and security threat necessitating immediate coordinated action and pooled funding by a global coalition of governments, institutions, companies and NGOs, Jim O'Neill says in his review's final report on the topic, which outlines a menu of options for accomplishing that – including a levy on the pharma sector – and says a supra-national entity will also be needed to tackle AMR.
2016 could prove an inflection point in the battle to confront AMR, as world leaders and the pharma industry move towards seriously embracing the theme and hopefully make lasting commitments to effectively combat antibiotic resistance, Jim O'Neill says in his eighth and final report. Meetings of groups, like the G20 and the UN General Assembly gatherings in September 2016, could be crucial in galvanising political consensus towards action at a global level.
"Tackling AMR is absolutely essential
The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.
The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.
PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.
